Skip to Content
Looking to save on your medications?  Find out how 

6 Interactions found for:

MiraLAX and ondansetron
Interactions Summary
  • 2 Major
  • 2 Moderate
  • 2 Minor
  • MiraLAX
  • ondansetron

Drug Interactions

Moderate
Ondansetron + Miralax

The following applies to the ingredients: Ondansetron and Polyethylene Glycol 3350 (found in Miralax)

Ondansetron can cause an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. The risk is increased if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances, such as low blood levels of magnesium or potassium. These electrolyte disturbances can occur with bowel cleansing preparations or excessive use of medications that have a laxative effect, such as polyethylene glycol 3350. Do not exceed the dose and duration recommended on the product label or prescribed by your doctor. You should seek immediate medical attention if you experience sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether taken together or separately. In addition, you should let your doctor know if you experience signs and symptoms of low magnesium or potassium blood level such as weakness, tiredness, drowsiness, dizziness, confusion, tingling, numbness, muscle pain, cramps, nausea, or vomiting. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Drug and Food Interactions

Moderate
Miralax + Food

The following applies to the ingredients: Polyethylene Glycol 3350 (found in Miralax)

Using polyethylene glycol 3350 together with a starch-based food thickener should generally be avoided. Combining these products may make the mixture thinner and less effective at thickening. According to product labeling, this could increase the risk of liquid going down the wrong way (aspiration) in people who have swallowing problems. Do not mix polyethylene glycol 3350 directly into starch-based thickened drinks or foods. Check the instructions on each product's packaging and follow your healthcare provider's or institution's guidance if you have questions or concerns.

Drug and Pregnancy Interactions

The following applies to the ingredients: Ondansetron

Professional Content

Safety has not been established during pregnancy.

AU TGA pregnancy category: B1
US FDA pregnancy category: Not assigned

Risk summary: No data are available on the use of this drug in pregnant women to inform a drug-related risk.

Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy.

AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out

References

  1. "Product Information. Zofran (ondansetron)." GlaxoSmithKline PROD (2001):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. "Product Information. Zuplenz (ondansetron)." Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc. (2010):

The following applies to the ingredients: Polyethylene Glycol 3350 (found in Miralax)

Professional Content

Use is not recommended unless clearly needed.

AU TGA pregnancy category: B1
US FDA pregnancy category: Not assigned

Animal studies have not been conducted. There are no controlled data in human pregnancy. Systemic exposure if negligible, so clinically significant exposure of the fetus is not expected.

AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

References

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. TGA. Therapeutic Goods Administration. Australian Drug Evaluation Committee "Prescribing medicines in pregnancy: an Australian categorisation of risk of drug use in pregnancy. http://www.tga.gov.au/docs/html/medpreg.htm" (2010):
  3. Briggs GG, Freeman RK. "Drugs in Pregnancy and Lactation." Philadelphia, PA: Wolters Kluwer Health (2015):

Drug and Breastfeeding Interactions

The following applies to the ingredients: Ondansetron

Professional Content

Breastfeeding is not recommended during use of this drug (AU, UK)
Use with caution (US)

Excreted into human milk: Unknown
Excreted into animal milk: Yes

Comments: The effects in the nursing infant are unknown.

References

  1. "Product Information. Zofran (ondansetron)." GlaxoSmithKline PROD (2001):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. "Product Information. Zuplenz (ondansetron)." Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc. (2010):
  5. United States National Library of Medicine "Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT" (2013):

The following applies to the ingredients: Polyethylene Glycol 3350 (found in Miralax)

Professional Content

This drug should be used only if clearly needed.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

References

  1. Cerner Multum, Inc. "Australian Product Information." O 0

Therapeutic Duplication Warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Switch to: Professional Interactions

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Disclaimer: This content should not be considered complete and should not be used in place of a call or visit to a healthcare professional. Use of this content is subject to our terms of use & medical disclaimer.